SLC5A2 and diabetes mellitus: Regarding diabetes treatment, 96 participants (93%) were treated with metformin, 48 (47%) with sodium-glucose co-transporter type 2 (SGLT2) inhibitors, 34 (33%) with glucagon-like peptide-1 (GLP-1) receptor agonists, and 34 (33%) with basal insulin (Supplementary Data Sheet S1-Supplementary Table S1).